Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusAGEN -2.32%43 OCF Margin % is -90.38% as of Jun. 2026. GuruFocus rates AGEN with a GF Score™ of 43/100 and a GF Value™ of $3.78 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 955 Biotechnology companies, Agenus ranks worse than 50.89% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Agenus's Cash Flow from Operations for the
three
months ended in Jun. 2026 was $-31.2 Mil. Agenus's Revenue for the
three
months ended in Jun. 2026 was $34.5 Mil. Therefore, Agenus's OCF Margin % for the quarter that ended in Jun. 2026 was -90.38%.
The historical data trend for Agenus's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agenus's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Agenus's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus (AGEN) has a OCF Margin % of -90.38% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Agenus and its competitors. According to the industry distribution chart, Agenus ranks #486 out of 955 companies in the Biotechnology industry, placing it in the top 50.9%.
Is Agenus' OCF Margin % too high?
Agenus' current OCF Margin % is -90.38%. Based on the distribution chart, Agenus ranks #486 out of 955 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Agenus has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' OCF Margin % compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #486 out of 955 companies for OCF Margin %. This places Agenus in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Agenus and its competitors. Agenus's current OCF Margin % is -90.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (AGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $7.16 — trading 89.3% above its estimated fair value. The current OCF Margin % is -90.38%. Agenus' overall GF Score™ is 43/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Agenus (AGEN), the current OCF Margin % is -90.38% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (AGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for AGEN:
OCF Margin %: -90.38%
GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score
Get the complete analysis for AGEN
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGEN has been successfully added to your 
